Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown origin, in which both genetic and environmental factors are involved. One such environmental factor is vitamin D, a vital hormone that plays a specific function in the immune system homeostasis, acting through a nuclear receptor (VDR) expressed in all immune cells. Several polymorphisms of the gene that encodes this receptor have been described. Though inconsistently, these polymorphisms have been associated with clinical manifestations and SLE development.
The aim of this study was to determine the possible association between VDR gene polymorphisms (BsmI, ApaI, TaqI e FokI) and SLE susceptibility and severity, in a cohort of lupus patients from the north of Portugal.
A total of 170 patients (F = 155, M = 15; age = 45 ± 13.4 years) with SLE (diagnosed according the American College of Rheumatology criteria) with at least five years of disease evolution and followed in the Autoimmune Disease Clinical Immunology Unit of Centro Hospitalar do Porto were studied. Patients and 192 ethnicity-matched controls were genotyped for BsmI (rs1544410), ApaI (rs7975232), TaqI (rs731236) and FokI (rs2228570) polymorphisms by TaqMan allelic discrimination assay. Disease severity was assessed by SLICC damage score, number of affected organs, number of severe flares and pharmacological history.
SLE patients with the CT genotype of FokI polymorphism have a higher SLICC value (p = 0.031). The same result was observed for the group of patients with the TT genotype of TaqI polymorphism (p = 0.046). No differences were observed in VDR genotype between patients and controls. Also, we observed that the other clinical features analysed were not influenced by VDR polymorphisms.
Our study confirms a possible role of VDR gene polymorphisms in SLE. A positive association was found between VDR polymorphisms and SLE severity (chronic damage). The presence of CT genotype of FokI and TT genotype of TaqI seems to confer a worse prognosis and may constitute a risk factor for higher long-term cumulative damage in SLE patients.
ChoiJKimSTCraftJ. The pathogenesis of systemic lupus erythematosus – an update. Curr Opin Immunol2012; 24: 651–657.
2.
AskanaseAShumKMitnickH. Systemic lupus erythematosus: An overview. Soc Work Health Care2012; 51: 576–586.
3.
KunzM. Lupus erythematosus. Part I: Epidemiology, genetics and immunology [article in German and English]. J Dtsch Dermatol Ges2013; 11: 709–719; quiz 720, 709–720; quiz 721.
4.
HolickMF. Vitamin D deficiency. N Engl J Med2007; 357: 266–281.
5.
BaekeFTakiishiTKorfHGysemansCMathieuC. Vitamin D: Modulator of the immune system. Curr Opinion Pharmacol2010; 10: 482–496.
6.
Ben-ZviIAranowCMackayM. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PloS One2010; 5: e9193–e9193.
7.
Ruiz-IrastorzaGGordoSOlivaresNEgurbideMVAguirreC. Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage. Arthritis Care Res (Hoboken)2010; 62: 1160–1165.
8.
KamenDL. Vitamin D in lupus – new kid on the block?Bull NYU Hosp Jt Dis2010; 68: 218–222.
9.
vinh quc LuongKNguyenLT. The beneficial role of vitamin D in systemic lupus erythematosus (SLE). Clin Rheumatol2012; 31: 1423–1435.
10.
KöstnerKDenzerNMüllerCSKleinRTilgenWReichrathJ. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: A review of the literature. Anticancer Res2009; 29: 3511–3536.
11.
de Azevêdo SilvaJMonteiro FernandesKTrés PancottoJA. Vitamin D receptor (VDR) gene polymorphisms and susceptibility to systemic lupus erythematosus clinical manifestations. Lupus2013; 22: 1110–1117.
12.
YangCYLeungPSAdamopoulosIEGershwinME. The implication of vitamin D and autoimmunity: A comprehensive review. Clin Rev Allergy Immunol2013; 45: 217–226.
13.
PetriMOrbaiAMAlarcónGS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
14.
BuyonJPPetriMAKimMY. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med2005; 142: 953–962.
15.
PetriMBuyonJKimM. Classification and definition of major flares in SLE clinical trials. Lupus1999; 8: 685–691.
16.
GladmanDGinzlerEGoldsmithC. Systemic lupus international collaborative clinics: Development of a damage index in systemic lupus erythematosus. J Rheumatol1992; 19: 1820–1821.
17.
BertsiasGKIoannidisJPAringerM. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: Report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis2010; 69: 2074–2082.
18.
BertsiasGKTektonidouMAmouraZ. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis2012; 71: 1771–1782.
19.
BertsiasGIoannidisJPBoletisJ. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis2008; 67: 195–205.
20.
PrietlBTreiberGPieberTRAmreinK. Vitamin D and immune function. Nutrients2013; 5: 2502–2521.
21.
ShoenfeldNAmitalHShoenfeldY. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol2009; 5: 99–105.
22.
ArnsonYAmitalHShoenfeldY. Vitamin D and autoimmunity: New aetiological and therapeutic considerations. Ann Rheum Dis2007; 66: 1137–1142.
23.
Tizaoui K, Kaabachi W, Hamzaoui A, Hamzaoui K. Association between vitamin D receptor polymorphisms and multiple sclerosis: Systematic review and meta-analysis of case-control studies. Cell Mol Immunol. Epub ahead of print 7 July 2014. DOI: 10.1038/cmi.2014.47.
24.
MaalejAPetit-TeixeiraEMichouLRebaiACornelisFAyadiH. Association study of VDR gene with rheumatoid arthritis in the French population. Genes Immunol2005; 6: 707–711.
25.
LeeYHBaeSCChoiSJJiJDSongGG. Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: A meta-analysis. Mol Biol Rep2011; 38: 3643–3651.
26.
TizaouiKKaabachiWHamzaouiAHamzaouiK. Contribution of VDR polymorphisms to type 1 diabetes susceptibility: Systematic review of case-control studies and meta-analysis. J Steroid Biochem Mol Biol2014; 143: 240–249.
27.
van EttenEVerlindenLGiuliettiA. The vitamin D receptor gene FokI polymorphism: Functional impact on the immune system. Eur J Immunol2007; 37: 395–405.
28.
RitterhouseLLCroweSRNiewoldTB. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis2011; 70: 1569–1574.
29.
OzakiYNomuraSNagahamaMYoshimuraCKagawaHFukuharaS. Vitamin-D receptor genotype and renal disorder in Japanese patients with systemic lupus erythematosus. Nephron2000; 85: 86–91.
30.
HuangCMWuMCWuJYTsaiFJ. Association of vitamin D receptor gene BsmI polymorphisms in Chinese patients with systemic lupus erythematosus. Lupus2002; 11: 31–34.
31.
LuoXYWuLJYangMH. Relationship of vitamin D receptor gene Fok I polymorphism with systemic lupus erythematosus [article in Chinese]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi2011; 27: 901–905.
32.
LuoXYWuLJChenL. The association of vitamin D receptor gene ApaI and BsmI polymorphism with systemic lupus erythematosus [article in Chinese]. Zhonghua Nei Ke Za Zhi2012; 51: 131–135.
33.
LuoXYYangMHWuFX. Vitamin D receptor gene BsmI polymorphism B allele, but not BB genotype, is associated with systemic lupus erythematosus in a Han Chinese population. Lupus2012; 21: 53–59.
34.
EmerahAAEl-ShalAS. Role of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D level in Egyptian female patients with systemic lupus erythematosus. Mol Biol Rep2013; 40: 6151–6162.
35.
MostowskaALianeriMWudarskiMOlesińskaMJagodzińskiPP. Vitamin D receptor gene BsmI, FokI, ApaI and TaqI polymorphisms and the risk of systemic lupus erythematosus. Mol Biol Rep2013; 40: 803–810.
36.
SakulpipatsinWVerasertniyomONantirujKTotemchokchyakarnKLertsrisatitPJanwityanujitS. Vitamin D receptor gene BsmI polymorphisms in Thai patients with systemic lupus erythematosus. Arthritis Res Ther2006; 8: R48–R48.
37.
AbbasiMRezaieyazdiZAfshariJTHatefMSahebariMSaadatiN. Lack of association of vitamin D receptor gene BsmI polymorphisms in patients with systemic lupus erythematosus. Rheumatol Int2010; 30: 1537–1539.
38.
MonticieloOATeixeira TdeMChiesJABrenolJCXavierRM. Vitamin D and polymorphisms of VDR gene in patients with systemic lupus erythematosus. Clin Rheumatol2012; 31: 1411–1421.
39.
KaletaBBogaczewiczJRobakE. Vitamin D receptor gene BsmI polymorphism in Polish patients with systemic lupus erythematosus. ISRN Endocrinol2013; 2013: 427818–427818.
40.
PeelenEKnippenbergSMurisAH. Effects of vitamin D on the peripheral adaptive immune system: A review. Autoimm Rev2011; 10: 733–743.
41.
JoshiSPantalenaLCLiuXK. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol2011; 31: 3653–3669.
42.
IsraniNGoswamiRKumarARaniR. Interaction of vitamin D receptor with HLA DRB1 0301 in type 1 diabetes patients from North India. PloS One2009; 4: e8023–e8023.
43.
RamagopalanSVMaugeriNJHandunnetthiL. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet2009; 5: e1000369–e1000369.
44.
Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. Epub ahead of print 16 May 2014. DOI: 10.1136/annrheumdis-2013-205171.
45.
LertratanakulAWuPDyerA. 25-Hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: Data from a large international inception cohort. Arthritis Care Res (Hoboken)2014; 66: 1167–1176.
